ArticleCancer & metabolism2022
Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer.
Article in Cancer & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Metabolomics and metabolites in cancer diagnosis and treatment.Molecular biomedicine · 2025Pooled it
- Untargeted plasma metabolomics identifies metabolite signatures associated with suicidality status in chronic schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Plasma metabolites, dietary intakes, and breast cancer incidence: a prospective case-cohort study in NutriNet-Santé.The American journal of clinical nutrition · 2026Article
- Metabolomic properties of the fluid from the surgical ligation after breast-conserving therapy and intraoperative radiotherapy.Scientific reports · 2026Article
- Integrated analysis of plasma metabolomics and proteomics reveals the biological characteristics of damp-heat and stasis-toxin syndrome in colorectal cancer.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Integrative proteomics and metabolomics advance early cancer detection and targeted therapy with emerging technologies and clinical applications.Discover oncology · 2026Review
- Serum untargeted metabolomics reveals key pathways in feline mammary carcinoma for comparative oncology.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Temporal Integration of Serum Proteomics, Metabolomics and MRI Tumor Volumetrics via Deep Learning Identifies Systemic Mediators of Glioblastoma Response to Chemoradiotherapy.Research square · 2026Article
- Integrative Analysis of 4-Hydroxynonenal-Modified Proteins and Plasma Metabolome in Breast Cancer Patients.Antioxidants (Basel, Switzerland) · 2026Article
- Multilayer metabolomic integration reveals bioenergetic disruption in Long COVID.Journal of translational medicine · 2026Article
- Combined analysis of metabolomics and transcriptomics reveals new indicators for the diagnosis and prognosis of colorectal cancer.Contemporary oncology (Poznan, Poland) · 2026Article
- Elucidating the causal effects of plasma metabolites on breast cancer from multiple perspectives.International journal of surgery (London, England) · 2026Article
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
- Article
- Bioinformatics Strategies in Breast Cancer Research.Biomolecules · 2025Review
- Spatial multi-omics reveals the potential involvement of SPP1Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Review
- Application of Metabolic Biomarkers in Breast Cancer: A Literature Review.Annals of laboratory medicine · 2025Review
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBreast cancer (BC) is the most commonly diagnosed cancer. Currently, mammography and breast ultrasonography are the main clinical screening methods for BC. Our study aimed to reveal the specific metabolic profiles of BC patients and explore the specific metabolic signatures in human plasma for BC diagnosis.
methodsThis study enrolled 216 participants, including BC patients, benign patients, and healthy controls (HC) and formed two cohorts, one training cohort and one testing cohort. Plasma samples were collected from each participant and subjected to perform nontargeted metabolomics and proteomics. The metabolic signatures for BC diagnosis were identified through machine learning.
resultsMetabolomics analysis revealed that BC patients showed a significant change of metabolic profiles compared to HC individuals. The alanine, aspartate and glutamate pathways, glutamine and glutamate metabolic pathways, and arginine biosynthesis pathways were the critical biological metabolic pathways in BC. Proteomics identified 29 upregulated and 2 downregulated proteins in BC. Our integrative analysis found that aspartate aminotransferase (GOT1), L-lactate dehydrogenase B chain (LDHB), glutathione synthetase (GSS), and glutathione peroxidase 3 (GPX3) were closely involved in these metabolic pathways. Support vector machine (SVM) demonstrated a predictive model with 47 metabolites, and this model achieved a high accuracy in BC prediction (AUC = 1). Besides, this panel of metabolites also showed a fairly high predictive power in the testing cohort between BC vs HC (AUC = 0.794), and benign vs HC (AUC = 0.879).
conclusionsThis study uncovered specific changes in the metabolic and proteomic profiling of breast cancer patients and identified a panel of 47 plasma metabolites, including sphingomyelins, glutamate, and cysteine could be potential diagnostic biomarkers for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.